The CECARI Study: Everolimus (Certican®) Initiation and Calcineurin Inhibitor Withdrawal in Maintenance Heart Transplant Recipients with Renal Insufficiency: A Multicenter, Randomized Trial

Table 2

Safety endpoints at year 3.

	Everolimus ()	CNI ()	value
Composite endpoint, (%)	9 (31.0)	7 (25.0)	0.50
Death	4 (13.8)	2 (7.1)	0.38
Treated acute rejection	3 (10.3)	1 (3.6)	0.09
MACE	5 (17.2)	6 (21.4)	0.96

MACE, major adverse cardiovascular event; CNI, calcineurin inhibitor.